8-K: Phio Pharmaceuticals Reports Q1 2026 Results, Advances PH-762 Trial

Phio Pharmaceuticals announced first quarter 2026 financial results, highlighting the completion of its PH-762 Phase 1b skin cancer trial and securing development agreements.

Summary

• Phio Pharmaceuticals reported its financial results for the quarter ended March 31, 2026.
• The company announced the completion of its Phase 1b clinical trial for PH-762, a potential treatment for skin cancer.
• Final data from the PH-762 trial is pending analysis, with an FDA submission planned for Q2 2026 to seek guidance on next steps.
• Phio secured approximately $23.7 million in net proceeds from equity financings and warrant exercises in 2025, extending its cash runway into the first half of 2027.
• Research and development expenses increased significantly by 215% to $2.8 million in Q1 2026 compared to Q1 2025, driven by clinical trial, CMC, and toxicology expenses for PH-762.
• General and administrative expenses rose by 39% to $1.4 million in Q1 2026.
• The net loss for the quarter was $4.0 million, an increase from $1.8 million in the prior year's quarter, due to higher operating expenses.
• As of March 31, 2026, the company had $17 million in cash and cash equivalents and entered into an At The Market (ATM) agreement to potentially raise up to $6.36 million.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, with key clinical trial completion and secured funding providing a stable outlook, despite increased operating expenses and net loss.

Positives

• Completion of the Phase 1b clinical trial for PH-762, with favorable safety and pathology data reported.
• Secured key development agreements for nonclinical toxicology and U.S. cGMP clinical supply manufacturing.
• Strengthened balance sheet in 2025, generating approximately $23.7 million in net proceeds from equity financings and warrant exercises.
• Extended cash runway into the first half of 2027, providing support for ongoing clinical development and operations.
• Presented Phase 1b clinical trial data for PH-762 at the American Academy of Dermatology (AAD) in March 2026 and at multiple conferences in April 2026.
• Entered into an At The Market (ATM) Agreement with H.C. Wainwright & Co. to potentially raise up to $6.36 million.

Negatives

• Net loss increased to $4.0 million for Q1 2026 from $1.8 million in Q1 2025.
• Research and development expenses increased significantly by 215% to $2.8 million in Q1 2026.
• General and administrative expenses increased by 39% to $1.4 million in Q1 2026.
• Cash and cash equivalents decreased to $17 million as of March 31, 2026, from $21 million as of December 31, 2025.

Risks

• The impact of future FDA interactions on the development of product candidates.
• The impact of inflationary pressures and recession fears on business and operations.
• The development of product candidates, including results from nonclinical, preclinical, and clinical activities.
• The ability to execute on business strategies and develop product candidates with collaboration partners.
• The timeline and duration for advancing product candidates into clinical development.
• The timing or likelihood of regulatory filings and approvals.
• The success of efforts to commercialize product candidates if approved.
• The scope of protection for intellectual property rights covering the technology platform.

Future Outlook

The company expects to submit to the FDA in the second quarter of 2026 to seek guidance on the next steps for the PH-762 development program. Research and development expenses are expected to continue increasing as the PH-762 program advances. The company's cash runway is projected to extend into the first half of 2027.

Management Comments

• "We are enthusiastic with the successful completion of our Phase 1b clinical trial which now positions us for upcoming FDA interface which we expect will clarify next steps in advancing the PH-762 development program," said Robert Bitterman, President and Chief Executive Officer.
• Management believes that research and development expenses will continue to increase as we continue to advance our PH-762 program.

Industry Context

StockSavvy.ai notes that Phio Pharmaceuticals' update aligns with the broader biopharmaceutical industry's focus on targeted therapies and gene silencing technologies for oncology. The company's progress in advancing its lead candidate, PH-762, through Phase 1b trials and seeking FDA guidance reflects a common pathway for clinical-stage biotech firms aiming to address unmet needs in cancer treatment.

Stakeholder Impact

• Shareholders: The report indicates continued investment in clinical development, which could lead to future value creation, but also shows increased net loss. The ATM agreement provides potential for further dilution but also capital for operations.
• Employees: Increased G&A expenses suggest potential growth in personnel or related costs.
• Creditors: The company's cash runway into H1 2027 suggests short-term solvency.

Next Steps

• Submit to the FDA in Q2 2026 to propose and seek guidance for next steps in PH-762 clinical study design.
• Continue advancing the PH-762 program, including ongoing clinical development, CMC, and toxicology expenses.
• Potentially raise up to $6.36 million through the ATM agreement.

Key Dates

Recommendation

The company has achieved a significant milestone with the completion of its Phase 1b trial for PH-762 and has secured funding to extend its runway. However, the increased net loss and the need for further FDA guidance and potential capital raises warrant a cautious 'hold' recommendation until more clarity on the next clinical steps and regulatory pathway emerges.

Keywords

Phio Pharmaceuticals, PH-762, siRNA, gene silencing, skin cancer, clinical trial, oncology, biopharmaceutical